Software: all-important, but all too easily overlooked
This article was originally published in Clinica
Executive Summary
Badly-written or inadequately-tested software can lead to adverse incidents with medtech products. Yet lack of attention to this issue results in regulators and manufacturers often citing software as a source of problems in real use. In this article, medtech consultant Trevor Lewis gives some much-needed pointers about how to start working towards the "state of the art" demanded by the EU Medical Devices Directive (93/42) and its revised version (2007/47) - which must be fully applied by March 21 2010
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.